Essilor : Disclosure of Share Capital and Voting Rights Outstanding as of
January 31, 2014
(Pursuant to Article L.233-8 II of the French Commercial Code and articles
221-1 and 223-16 of the General Regulations of the Autorité des Marchés
CHARENTON-LE-PONT, France -- February 5, 2014
Regulatory News :
As of January 31, 2014, shares and voting rights outstanding of Essilor
(Paris:EI), the world leader in ophthalmic optics, broke down as follows:
January 31, 2014
Shares outstanding 214,752,704
Exercisable voting rights 226,852,045
Total voting rights, based on all outstanding shares, 231,306,136
including shares stripped of their voting rights*
(*) Shares held by the Company.
The world’s leading ophthalmic optics company, Essilor designs, manufactures
and markets a wide range of lenses to improve and protect eyesight. Its
corporate mission is to enable everyone around the world to access lenses that
meet his or her unique vision requirements. To support this mission, the
Company allocates more than €150 million to research and innovation every
year, in a commitment to continuously bring new, more effective products to
market. Essilor’s flagship brands are Varilux^®, Crizal^®, Definity^®,
Xperio^®, Optifog™ and Foster Grant^®. It also develops and markets equipment,
instruments and services for eyecare professionals.
Essilor reported consolidated revenue of more than €5 billion in 2013 and
employs more than 50,000 people. It operates in some 100 countries with 22
plants, more than 400 prescription laboratories and edging facilities, as well
as several research and development centers around the world.
For more information, please visit www.essilor.com.
The Essilor share trades on the NYSE Euronext Paris market and is included in
the Euro Stoxx 50 and CAC 40 indices.
Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP
Investor Relations and Financial Communications
Phone: +33 (0)1 49 77 42 16
Press spacebar to pause and continue. Press esc to stop.